367 related articles for article (PubMed ID: 36569829)
1. Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma.
Xie F; Chen B; Yang X; Wang H; Zhang G; Wang Y; Wang Y; Zhang N; Xue J; Long J; Li Y; Sun H; Xun Z; Liu K; Chen X; Song Y; Yang X; Lu Z; Mao Y; Sang X; Lu Y; Zhao H
Front Immunol; 2022; 13():1052937. PubMed ID: 36569829
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Ng KYY; Wong LWJ; Ang AJS; Lee AWX; Tay DSH; Tan JJE; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2023 Jun; 19(3):312-319. PubMed ID: 35950298
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of bevacizumab as a salvage therapy for patients with advanced hepatocellular carcinoma targeting immune tolerance.
Zhang L; Xue J; Zhang N; Wang Y; Yang X; Wang S; Piao M; Liu K; Zhu C; Wang Y; Chao J; Ning C; Zhang X; Xun Z; Li Y; Sun H; Yang X; Zhao L; Zhao H
Am J Cancer Res; 2023; 13(8):3582-3590. PubMed ID: 37693157
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety and efficacy of molecular-targeted drugs, immune checkpoint inhibitors, hepatic arterial infusion chemotherapy and their combinations in advanced hepatocellular carcinoma: findings from advances in landmark trials.
Pan Y; Wang R; Hu D; Xie W; Fu Y; Hou J; Xu L; Zhang Y; Chen M; Zhou Z
Front Biosci (Landmark Ed); 2021 Oct; 26(10):873-881. PubMed ID: 34719212
[No Abstract] [Full Text] [Related]
7. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
8. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract][Full Text] [Related]
9. Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients.
Lin PT; Teng W; Jeng WJ; Lin CY; Lin SM; Sheen IS
Eur J Gastroenterol Hepatol; 2022 Feb; 34(2):213-219. PubMed ID: 33177386
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
Chen K; Wei W; Liu L; Deng ZJ; Li L; Liang XM; Guo PP; Qi LN; Zhang ZM; Gong WF; Huang S; Yuan WP; Ma L; Xiang BD; Li LQ; Zhong JH
Cancer Immunol Immunother; 2022 May; 71(5):1063-1074. PubMed ID: 34559308
[TBL] [Abstract][Full Text] [Related]
15. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
Wang R; Lin N; Mao B; Wu Q
J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
[TBL] [Abstract][Full Text] [Related]
17. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qiao Q; Han C; Ye S; Li J; Shao G; Bai Y; Xu A; Sun M; Wang W; Wu J; Huang M; Song L; Huang L; Liu T; Liu W; Wang ZM; Li B; Xia M; Bai L
Front Immunol; 2023; 14():1238667. PubMed ID: 37942328
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
